Immunocore Holdings plc Contract with Customer, Refund Liability
Immunocore Holdings plc (IMCR) had Contract with Customer, Refund Liability of $161.68 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Revenue from Contract with Customer › Contract with Customer, Refund Liability
us-gaap:ContractWithCustomerRefundLiability · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Refund Liability $161.68M.
- 2026-03-31: Contract with Customer, Refund Liability $144.52M.
- 2025-12-31: Contract with Customer, Refund Liability $132.78M.
- 2025-09-30: Contract with Customer, Refund Liability $170.24M.
| Period end | Contract with Customer, Refund Liability |
|---|---|
| 2026-06-30 | $161.68M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $144.52M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $132.78M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $170.24M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $149.47M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $121.29M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $110.92M 10-K · filed 2026-02-25 |
| 2024-09-30 | $133.57M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $107.02M 10-Q · filed 2024-08-08 |
| 2023-12-31 | $66.73M 10-K · filed 2026-02-25 |
| 2022-12-31 | $30.92M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |